Form 4: Tandem Diabetes Care EVP Leigh Vosseller Reports Stock Transactions

EVP and CFO of Tandem Diabetes Care, Leigh Vosseller, reports acquisition and disposal of company stock and derivative securities.

Summary

• Leigh Vosseller, EVP & CFO of Tandem Diabetes Care, filed a Form 4 detailing changes in beneficial ownership.
• On May 28, 2024, Vosseller acquired 406 shares of common stock through the vesting of restricted stock units (RSUs).
• Also on May 28, 2024, 145 shares were withheld to satisfy tax obligations related to the RSU vesting at a price of $51.73 per share.
• Vosseller was also granted 17,946 restricted stock units (RSUs) and 17,946 performance stock units (PSUs) on May 23, 2024.
• Following these transactions, Vosseller directly owns 18,833 shares of common stock and indirectly owns 11,860 shares through the Leigh A. Vosseller Trust.
• Vosseller also holds 17,946 RSUs and 17,946 PSUs.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment as it reports routine stock transactions. The grants of RSUs and PSUs are generally positive, but the overall impact is not significant.

Positives

• The grant of RSUs and PSUs to Vosseller aligns her interests with the long-term performance of the company.
• Vesting schedules for RSUs and PSUs encourage continued service and achievement of performance goals.

Risks

• The value of the RSUs and PSUs is contingent on the future stock price and performance of Tandem Diabetes Care.
• If minimum performance metrics are not met, the PSUs will not vest.

Future Outlook

The vesting of RSUs and PSUs is subject to continued service and, in the case of PSUs, the achievement of pre-defined performance metrics as of December 31, 2026.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and alignment with shareholder interests.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the medical device industry to incentivize executives.
• Companies like Insulet and Dexcom also utilize RSUs and PSUs as part of their executive compensation packages.
• The vesting schedules and performance metrics associated with these awards are typically designed to align with long-term growth and profitability goals.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholders due to the change in ownership.
• The vesting of RSUs and PSUs incentivizes the executive to contribute to the company's success, which benefits all stakeholders.

Key Dates